ABSTRACT
This paper presents a woman in her 70's with G-CSF producing anaplastic carcinoma of the pancreas(Stage IVb)who underwent chemotherapy by S-1 alone. On FDG-PET after the first course, accumulation of FDG was impaired remarkably. After the second course, the patient died of carcinomatous pleuritis and peritonitis on the 88th day after initiation of treatment. G-CSF producing anaplastic carcinoma of the pancreas is extremely rare and there are no reports with regard to response evaluation by FDG-PET. Thus, this case has significant clinical value.
Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Carcinoma/diagnostic imaging , Oxonic Acid/therapeutic use , Pancreatic Neoplasms/diagnostic imaging , Positron-Emission Tomography , Tegafur/therapeutic use , Aged , Autopsy , Carcinoma/drug therapy , Carcinoma/metabolism , Drug Combinations , Fatal Outcome , Female , Fluorodeoxyglucose F18 , Granulocyte Colony-Stimulating Factor/biosynthesis , Humans , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/metabolism , Pleurisy/etiologyABSTRACT
A 37-year-old man underwent lobectomy of the right liver for granulocyte colony-stimulating factor (G-CSF) producing hepatocellular carcinoma accompanying type B hepatitis. Within two months after the surgery, lung metastases were revealed and administration of sorafenib was begun, however, the lung metastases continued to enlarge. Changing the patient's medication to tegafur-uracil provided remarkable reduction of the lung metastases. The patient is alive two years after diagnosis and receives outpatient chemotherapy. We concluded that this case is valuable with regard to the extreme rarity of G-CSF producing hepatocellular carcinoma and its successful treatment in this case.
